Home/Filings/4/0001562180-22-000156
4//SEC Filing

Danos Olivier 4

Accession 0001562180-22-000156

CIK 0001590877other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 9:04 PM ET

Size

13.2 KB

Accession

0001562180-22-000156

Insider Transaction Report

Form 4
Period: 2022-01-01
Danos Olivier
Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2021-06-30$33.02/sh+555$18,32719,598 total
  • Award

    Common Stock

    2021-12-31$27.80/sh+1$2819,599 total
  • Tax Payment

    Common Stock

    2022-01-01$32.70/sh1,221$39,92718,378 total
  • Award

    Common Stock

    2022-01-03+10,70029,078 total
  • Award

    Stock Option (Right to Buy)

    2022-01-03+51,10051,100 total
    Exercise: $34.31Exp: 2032-01-03Common Stock (51,100 underlying)
Footnotes (6)
  • [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is exempt under Rule 16b-3(c).
  • [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2021.
  • [F3]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is exempt under Rule 16b-3(c).
  • [F4]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2021.
  • [F5]Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
  • [F6]25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.

Issuer

REGENXBIO Inc.

CIK 0001590877

Entity typeother

Related Parties

1
  • filerCIK 0001701180

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 9:04 PM ET
Size
13.2 KB